- CA$130.80m
- CA$170.26m
- $55.50m
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease
Canada Research Roundup: Aritzia, Cameco, HLS Therapeutics
Brief: Hls Therapeutics Announces Reimbursement For Vascepa Under Nova Scotia's Provincial Drug Plan
Canada Research Roundup: ARC Resources ,First Nordic Metals, Tantalus Systems
Canada Research Roundup: Canadian National Railway, HLS Therapeutics, Rogers Communications
Canada Research Roundup: Dollarama, Mag Silver, Nexgen Energy
Brief: HLS Therapeutics Announces Q3 2024 Financial Results
Canada Research Roundup: Air Canada, Bank of Montreal, Emera
Brief: HLS Announces Reimbursement For Vascepa Under Alberta's Provincial Drug Plan
Brief: HLS Therapeutics Announces The Sale Of Its Xenpozyme Royalty Interest To DRI Healthcare Trust
Brief: Hls Therapeutics Announces Fiscal 2023 Financial Results
Brief: HLS Announces That Vascepa Is Now Reimbursed By British Columbia's Provincial Drug Plan